FLI1 Rabbit Polyclonal Antibody (HA500149)

UNIPROT #

Q01543

PROTEIN NAME

FLI1

SYNONYMS

ERGB transcription factor antibody;Ewing Sarcoma breakpoint region 2 antibody;EWSR 2 antibody;EWSR2 antibody;FLI 1 antibody;FLI 1 proto oncogene antibody;Fli-1 proto-oncogene, ETS transcription factor antibody;FLI1 antibody;FLI1 EWS fusion gene antibody;FLI1 proto oncogene antibody;FLI1_HUMAN antibody;Friend leukemia integration 1 (FLI1) transcription factor antibody;Friend leukemia integration 1 transcription factor antibody;Friend leukemia virus integration 1 antibody;Proto-oncogene Fli-1 antibody;Sarcoma breakpoint region 2 (EWSR2) antibody;SIC 1 antibody;SIC1 antibody;Transcription factor ERGB antibody;Viral integration region FLI1 antibody;Viral integration region FLI1, mouse, homolog of antibody

SUBCELLULAR LOCATION

Nucleus.

FUNCTION

Fli-1 is a member of the ETS transcription factor family that was first identified in erythroleukemias induced by Friend Murine Leukemia Virus (F-MuLV). Fli-1 is activated through retroviral insertional mutagenesis in 90% of F-MuLV-induced erythroleukemias. The constitutive activation of fli-1 in erythroblasts leads to a dramatic shift in the Epo/Epo-R signal transduction pathway, blocking erythroid differentiation, activating the Ras pathway, and resulting in massive Epo-independent proliferation of erythroblasts. These results suggest that Fli-1 overexpression in erythroblasts alters their responsiveness to Epo and triggers abnormal proliferation by switching the signaling event(s) associated with terminal differentiation to proliferation. In addition to Friend erythroleukemia, proviral integration at the fli-1 locus also occurs in leukemias induced by the 10A1, Graffi, and Cas-Br-E viruses. Fli-1 aberrant expression is also associated with chromosomal abnormalities in humans. In pediatric Ewing’s sarcoma a chromosomal translocation generates a fusion of the 5’ transactivation domain of EWSR1 (also known as EWS) with the 3’ Ets domain of Fli-1. The resulting fusion oncoprotein, EWS/Fli-1, acts as an aberrant transcriptional activator. with strong transforming capabilities. A recent study has demonstrated high levels of Fli-1 expression in several benign and malignant neoplasms using immunohistochemistry.